S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

KTTA Pasithea Therapeutics Corporation

6.92

0.00 (0.00%)

May 02 2024 - Closed

Delayed by 15 minutes

Pasithea Therapeutics rockets 132% after adding esketamine nasal spray to U.K. offerings

To read the full story on Seeking Alpha, click here.

Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics Corporation News

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Monday 29 April 2024 (4 days ago) • GlobeNewswire Inc.

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Wednesday 24 April 2024 (1 week ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Tuesday 13 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 18 January 2024 (3 months ago) • Edgar (US Regulatory)

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Monday 8 January 2024 (4 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 2 January 2024 (4 months ago) • Edgar (US Regulatory)

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Tuesday 2 January 2024 (4 months ago) • GlobeNewswire Inc.

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Thursday 28 December 2023 (4 months ago) • Edgar (US Regulatory)

More Pasithea Therapeutics Corporation News Articles

Voip Pal Com (QB)

BlackStar Enterprise (PK)

Global Developments (PK)

Brookmount Explorations (PK)

Trump Media and Technology

Globestar Therapeutics (PK)

Atacama Resources (PK)

CBD of Denver (PK)

International Star (PK)

Bell Buckle (PK)

Mullen Automotive

Therapeutic Solutions (PK)

FuelCell Energy

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions